NPC1L1 and diabetes mellitus: MR studies using LDL-C-lowering drugs’ target genes—such as HMGCR, PCSK9, and NPC1L1 variants—as genetic instruments have consistently demonstrated an inverse association between LDL-C and DM [10,18,19,20].